3.31
0.61%
0.02
Kiora Pharmaceuticals Inc stock is traded at $3.31, with a volume of 11,034.
It is up +0.61% in the last 24 hours and down -4.61% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.29
Open:
$3.25
24h Volume:
11,034
Relative Volume:
0.43
Market Cap:
$9.77M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.3594
EPS:
-9.2108
Net Cash Flow:
$7.14M
1W Performance:
-11.42%
1M Performance:
-4.61%
6M Performance:
-35.48%
1Y Performance:
-36.04%
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
781-788-8869
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Compare KPRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
KPRX | 3.3191 | 9.77M | 0 | 2.81M | 7.14M | -9.2108 |
VRTX | 467.50 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 761.42 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.58 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.64 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com
Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia
Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan
CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK
Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Upgraded to Strong-Buy at Maxim Group - Defense World
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiora Pharmaceuticals Inc Stock (KPRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Shapiro Aron | Director |
Sep 10 '24 |
Buy |
3.60 |
3,000 |
10,800 |
3,000 |
Walters-Hoffert Lisa | Director |
Aug 19 '24 |
Buy |
3.86 |
1,250 |
4,825 |
1,250 |
TYLE PRAVEEN | Director |
Aug 19 '24 |
Buy |
3.96 |
5,000 |
19,800 |
5,014 |
Tosca Melissa | CFO |
Aug 14 '24 |
Buy |
3.21 |
2,000 |
6,420 |
13,599 |
Tosca Melissa | EVP Finance |
Jun 14 '24 |
Buy |
5.25 |
100 |
525 |
3,979 |
Daniels Eric Joseph | Chief Development Officer |
Jun 14 '24 |
Buy |
5.29 |
1,431 |
7,570 |
11,222 |
Parsons Erin | Director |
Jun 13 '24 |
Buy |
4.88 |
5,260 |
25,669 |
5,260 |
Strem Brian M. | President and CEO |
Jun 13 '24 |
Buy |
5.00 |
3,000 |
14,997 |
14,531 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):